Several clinical trials of BET-BRD inhibitors with desirable pharmacokinetic properties have been initiated in multiple cancer types, including trials with OTX015 for the treatment of acute leukemia (ClinicalTrials.gov identifier: NCT01713582), CPI-0610 for progressive lymphoma (ClinicalTrials.gov identifier: NCT01949883), I-BET-762 and TEN-010 for NUT midline carcinoma (ClinicalTrials.gov identifier: NCT01587703, NCT01987362), and a dose escalation and cohort expansion study for TEN-010 in patients with AML and myelodysplastic syndrome (ClinicalTrials.gov identifier: NCT02308761). The gene discussed is DNER; the disease is nut midline carcinoma.